Age-dependent manifestations and case definitions of paediatric Zika: a prospective cohort study.


Journal

The Lancet. Infectious diseases
ISSN: 1474-4457
Titre abrégé: Lancet Infect Dis
Pays: United States
ID NLM: 101130150

Informations de publication

Date de publication:
03 2020
Historique:
received: 03 05 2019
revised: 01 09 2019
accepted: 27 09 2019
pubmed: 25 12 2019
medline: 1 7 2020
entrez: 25 12 2019
Statut: ppublish

Résumé

Paedeatric Zika remains an understudied topic. WHO and the Pan American Health Organization (PAHO) Zika case definitions have not been assessed in children. We aimed to characterise clinical profiles and evaluate the diagnostic performance of the WHO and PAHO case definitions in a large cohort of paediatric Zika cases. From January, 2016 to February, 2017, encompassing the major 2016 Zika epidemic, participants in the Pediatric Dengue Cohort Study (PDCS) in Managua, Nicaragua, were encouraged to visit the study health centre at first indication of any illness. PDCS participants were aged 2-14 years, healthy at enrolment, and recruited before the initiation of the present study. Molecular and serological assays were used to test participants exhibiting any of four broad clinical profiles suspected of resulting from a symptomatic Zika virus infection. These clinical profiles were: fever and at least two of headache, retro-orbital pain, myalgia, arthralgia, rash, haemorrhagic manifestations, and leukopenia; fever and at least two of nausea or vomiting, rash, aches and pains, positive tourniquet test, leukopenia, and any dengue warning sign; undifferentiated fever without evident cause, with or without any other clinical finding; and afebrile rash with or without any other clinical finding. We characterised acute clinical findings (signs, symptoms, and complete blood counts) in both Zika cases and non-Zika cases. We prospectively followed a cohort of about 3700 children, of which 1110 were deemed eligible for inclusion. Four participants with laboratory-confirmed Zika (three co-infections with dengue virus, one missing complete blood count data) and two participants who were non-Zika cases (missing complete blood count data) were excluded from analysis. We analysed 556 laboratory-confirmed Zika and 548 non-Zika cases. The WHO case definition captured 176 confirmed Zika cases, and the PAHO definition 109 confirmed Zika cases, who presented with the most clinical findings and a dengue-like clinical profile. The remaining two thirds of Zika cases, principally characterised by undifferentiated fever or afebrile rash, were missed. Among Zika cases, rash (n=440)-particularly generalised erythematous rash (n=334)-fever (n=333), leukopenia (n=217), and headache (n=203) were most common and peaked within 3 days of illness onset. The most common Zika presentation over the first week of illness was rash only (n=80). The sensitivity of Zika case definitions increased across paediatric age (from 11·3% to 56·1% for the WHO case definition and from 6·0% to 36·6% for the PAHO case definition), as the prevalence of most clinical findings (particularly arthralgia) increased with age, irrespective of previous dengue virus infection. Consequently, Zika manifested differently across paediatric age; older Zika cases presented with a dengue-like clinical profile while younger Zika cases presented with undifferentiated fever or afebrile rash. We provide the most thorough description of paediatric Zika to date. Most paediatric Zika cases go undetected under the WHO and PAHO case definitions, suggesting that current standards for Zika case ascertainment require revision. Zika manifests with mild but differing clinical profiles across paediatric age, presenting major challenges to diagnosis, surveillance, and efforts to control future Zika epidemics. US National Institutes of Health.

Sections du résumé

BACKGROUND
Paedeatric Zika remains an understudied topic. WHO and the Pan American Health Organization (PAHO) Zika case definitions have not been assessed in children. We aimed to characterise clinical profiles and evaluate the diagnostic performance of the WHO and PAHO case definitions in a large cohort of paediatric Zika cases.
METHODS
From January, 2016 to February, 2017, encompassing the major 2016 Zika epidemic, participants in the Pediatric Dengue Cohort Study (PDCS) in Managua, Nicaragua, were encouraged to visit the study health centre at first indication of any illness. PDCS participants were aged 2-14 years, healthy at enrolment, and recruited before the initiation of the present study. Molecular and serological assays were used to test participants exhibiting any of four broad clinical profiles suspected of resulting from a symptomatic Zika virus infection. These clinical profiles were: fever and at least two of headache, retro-orbital pain, myalgia, arthralgia, rash, haemorrhagic manifestations, and leukopenia; fever and at least two of nausea or vomiting, rash, aches and pains, positive tourniquet test, leukopenia, and any dengue warning sign; undifferentiated fever without evident cause, with or without any other clinical finding; and afebrile rash with or without any other clinical finding. We characterised acute clinical findings (signs, symptoms, and complete blood counts) in both Zika cases and non-Zika cases.
FINDINGS
We prospectively followed a cohort of about 3700 children, of which 1110 were deemed eligible for inclusion. Four participants with laboratory-confirmed Zika (three co-infections with dengue virus, one missing complete blood count data) and two participants who were non-Zika cases (missing complete blood count data) were excluded from analysis. We analysed 556 laboratory-confirmed Zika and 548 non-Zika cases. The WHO case definition captured 176 confirmed Zika cases, and the PAHO definition 109 confirmed Zika cases, who presented with the most clinical findings and a dengue-like clinical profile. The remaining two thirds of Zika cases, principally characterised by undifferentiated fever or afebrile rash, were missed. Among Zika cases, rash (n=440)-particularly generalised erythematous rash (n=334)-fever (n=333), leukopenia (n=217), and headache (n=203) were most common and peaked within 3 days of illness onset. The most common Zika presentation over the first week of illness was rash only (n=80). The sensitivity of Zika case definitions increased across paediatric age (from 11·3% to 56·1% for the WHO case definition and from 6·0% to 36·6% for the PAHO case definition), as the prevalence of most clinical findings (particularly arthralgia) increased with age, irrespective of previous dengue virus infection. Consequently, Zika manifested differently across paediatric age; older Zika cases presented with a dengue-like clinical profile while younger Zika cases presented with undifferentiated fever or afebrile rash.
INTERPRETATION
We provide the most thorough description of paediatric Zika to date. Most paediatric Zika cases go undetected under the WHO and PAHO case definitions, suggesting that current standards for Zika case ascertainment require revision. Zika manifests with mild but differing clinical profiles across paediatric age, presenting major challenges to diagnosis, surveillance, and efforts to control future Zika epidemics.
FUNDING
US National Institutes of Health.

Identifiants

pubmed: 31870907
pii: S1473-3099(19)30547-X
doi: 10.1016/S1473-3099(19)30547-X
pmc: PMC7085943
mid: NIHMS1547920
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

371-380

Subventions

Organisme : NIAID NIH HHS
ID : P01 AI106695
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI099631
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI118610
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Références

Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):9294-9299
pubmed: 30150394
N Engl J Med. 2009 Jun 11;360(24):2536-43
pubmed: 19516034
PLoS One. 2017 Jun 26;12(6):e0179725
pubmed: 28650987
PLoS Curr. 2016 Apr 15;8:
pubmed: 27158557
Clin Infect Dis. 2018 Nov 13;67(11):1760-1767
pubmed: 29697796
JAMA Pediatr. 2017 Mar 1;171(3):288-295
pubmed: 27812690
J Infect Dis. 2010 Jan 1;201(1):5-14
pubmed: 19929380
MMWR Morb Mortal Wkly Rep. 2016 Oct 07;65(39):1082-1085
pubmed: 27711041
Bull World Health Organ. 2018 Jun 01;96(6):402-413D
pubmed: 29904223
Clin Infect Dis. 2017 May 15;64(10):1445-1448
pubmed: 28186536
JAMA Pediatr. 2018 Jul 1;172(7):686-693
pubmed: 29813148
Trans R Soc Trop Med Hyg. 1952 Sep;46(5):509-20
pubmed: 12995440
Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):728-33
pubmed: 26729879
Stat Methods Med Res. 1995 Sep;4(3):187-96
pubmed: 8548102
PLoS Negl Trop Dis. 2019 Mar 28;13(3):e0007213
pubmed: 30921321
Int J Infect Dis. 2016 Apr;45:95-7
pubmed: 26923081
Am J Epidemiol. 2009 Jul 1;170(1):120-9
pubmed: 19435864
Science. 2017 Nov 17;358(6365):929-932
pubmed: 29097492
PLoS Med. 2019 Jan 22;16(1):e1002726
pubmed: 30668565
Clin Microbiol Rev. 2016 Jul;29(3):487-524
pubmed: 27029595
Sci Rep. 2016 Jun 17;6:28070
pubmed: 27312324
Clin Infect Dis. 2020 Jan 2;70(2):227-231
pubmed: 30855072
Clin Infect Dis. 2016 Dec 15;63(12):1584-1590
pubmed: 27578819
PLoS Negl Trop Dis. 2016 Apr 12;10(4):e0004636
pubmed: 27070912

Auteurs

Raquel Burger-Calderon (R)

Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, USA; Sustainable Sciences Institute, Managua, Nicaragua.

Fausto Bustos Carrillo (F)

Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, USA; Division of Epidemiology and Biostatistics, School of Public Health, University of California, Berkeley, Berkeley, CA, USA.

Lionel Gresh (L)

Sustainable Sciences Institute, Managua, Nicaragua.

Sergio Ojeda (S)

Sustainable Sciences Institute, Managua, Nicaragua.

Nery Sanchez (N)

Sustainable Sciences Institute, Managua, Nicaragua.

Miguel Plazaola (M)

Sustainable Sciences Institute, Managua, Nicaragua.

Leah Katzelnick (L)

Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, USA.

Brenda Lopez Mercado (BL)

Sustainable Sciences Institute, Managua, Nicaragua.

Jairo Carey Monterrey (JC)

Sustainable Sciences Institute, Managua, Nicaragua.

Douglas Elizondo (D)

Sustainable Sciences Institute, Managua, Nicaragua.

Sonia Arguello (S)

Sustainable Sciences Institute, Managua, Nicaragua.

Andrea Nuñez (A)

Sustainable Sciences Institute, Managua, Nicaragua; National Virology Laboratory, Centro Nacional de Diagnóstico y Referencia, Ministry of Health, Managua, Nicaragua.

Aubree Gordon (A)

Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, USA.

Angel Balmaseda (A)

Sustainable Sciences Institute, Managua, Nicaragua; National Virology Laboratory, Centro Nacional de Diagnóstico y Referencia, Ministry of Health, Managua, Nicaragua.

Guillermina Kuan (G)

Centro de Salud Sócrates Flores Vivas, Ministry of Health, Managua, Nicaragua.

Eva Harris (E)

Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, USA. Electronic address: eharris@berkeley.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH